Filing Overview
Pasithea Therapeutics Corp. filed a Form 8-K dated December 19, 2023, reporting results of its 2023 annual stockholders’ meeting and related corporate actions. The filing does not provide quarterly or annual financial results.
Business Context and Reporting Period
The filing concerns the Company’s annual meeting, originally adjourned on November 29, 2023, and actions taken on December 19, 2023. Pasithea is an emerging growth company with common stock and warrants listed on The Nasdaq Capital Market under KTTA and KTTAW.
Key Financial Metrics
The filing text does not provide clear values for revenue, net income or loss, cash flow, margins, debt, cash balances, liquidity, operating expenses, or other financial metrics.
Material Corporate Actions
- Stockholders approved the 2023 Stock Incentive Plan, reserving 2,500,000 shares of common stock and permitting the rollover of certain unused or forfeited shares and awards from the 2021 Incentive Plan. The plan became effective upon stockholder approval.
- Stockholders authorized the Board, through December 19, 2024, to effect a reverse stock split at a ratio ranging from 1-for-2 to 1-for-20. The Board may determine the exact ratio without further stockholder approval. Authorized common shares would be correspondingly reduced, but not below 100,000,000 shares.
- All five director nominees were elected for one-year terms, subject to any changes resulting from the pending board-classification proposal.
- Stockholders ratified Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Voting Results
| Proposal | Result | Key vote information |
|---|---|---|
| Director elections | Approved | Each nominee received between 11,369,003 and 11,433,844 votes for. |
| Reverse stock split authorization | Approved | 13,432,469 for; 1,181,664 against; 156,671 abstentions. |
| 2023 Stock Incentive Plan | Approved | 9,196,502 for; 1,520,422 against; 987,467 abstentions; 3,066,413 broker non-votes. |
| Ratification of Marcum LLP | Approved | 13,742,119 for; 992,581 against; 36,104 abstentions. |
Pending Matters, Outlook, and Risks
- The annual meeting was partially adjourned until December 28, 2023, solely to vote on proposals concerning amendment and restatement of the certificate of incorporation, board classification and removal of directors, stockholder action by written consent, and the voting threshold for amending the bylaws.
- These pending proposals require approval by holders of a majority of the outstanding voting power, with broker non-votes treated as votes against.
- The authorized reverse stock split could materially affect the number of outstanding shares and per-share trading metrics, although the filing does not state whether or when the Board will implement it.
- Approval of the incentive plan may increase potential equity-based compensation and future share dilution; the filing does not provide an estimated expense or dilution amount.
- The filing provides no formal financial guidance or management outlook.
Investor Verification Items
- Verify whether the Board subsequently implemented the authorized reverse stock split, including the selected ratio and effective date.
- Verify the December 28, 2023 results for the four adjourned proposals.
- Review the 2023 Stock Incentive Plan for total share capacity, rollover provisions, vesting terms, and potential dilution.
- Review subsequent financial filings for cash runway, financing needs, operating losses, and any going-concern or liquidity disclosures.
- Confirm the final 2023 audit status and any subsequent changes involving Marcum LLP.